Product
/
/
/
/
Diabetes medication Sitagliptin Phosphate Monohydrate 654671-77-9

Popular information

Diabetes medication Sitagliptin Phosphate Monohydrate 654671-77-9

【Alias】 7-[(3R) -3-amino-1-oxo-4- (2,4,5-trifluorophenyl) butyl] -5,6,7,8-tetrahydro-3-trifluoro Methyl-1,2,4-triazolo [4,3-a] pyrazine phosphate monohydrate
【Catalog number】AP2401
【CAS #】654671-77-9
【Molecular formula】C16H20F6N5O6P
【Product Brief】Sitagliptin phosphate monohydrate, the English name is Sitagliptin Phosphate Monohydrate, and the American Chemical Abstracts Registration Number is cas 654671-77-9.
English Name : Sitagliptin Phosphate Monohydrate
CAS# : 654671-77-9
产品描述
[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]

 

Diabetes medication

Sitagliptin Phosphate Monohydrate
CAS # 654671-77-9
US-DMF No. 29226

Alias ​​7-[(3R) -3-amino-1-oxo-4- (2,4,5-trifluorophenyl) butyl] -5,6,7,8-tetrahydro-3-trifluoro Methyl-1,2,4-triazolo [4,3-a] pyrazine phosphate monohydrate

Catalog number AP2401

CAS # 654671-77-9

Molecular formula C16H20F6N5O6P

Molecular weight 523.32

Structural formula

威智医药

Product introduction

CAS 654671-77-9

US-DMF No. 29226

Sitagliptin phosphate monohydrate, the English name is Sitagliptin Phosphate Monohydrate, and the American Chemical Abstracts Registration Number is cas 654671-77-9.

Sitagliptin phosphate monohydrate (cas 654671-77-9) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which controls blood glucose levels by protecting endogenous incretin and enhancing its effect. Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are incretins released against dietary intake. GLP-1 and GIP can increase insulin synthesis and release from islet β cells through intracellular signaling pathways. GLP-1 can also reduce glucagon secretion from islet α cells and reduce liver glucose production. However, both GLP-1 and GIP are rapidly metabolized by DPP-4, resulting in a loss of their insulinotropic effects. This medicine inhibits the degradation of incretin by DPP-4, so it can enhance the functions of GLP-1 and GIP, increase the release of insulin and reduce the glucagon level in the circulation (this effect is glucose-dependent). This drug selectively inhibits DPP-4 and has no inhibitory activity on DPP-8 or DPP-9. Can be used for the treatment of type 2 diabetes.

扫二维码用手机看
未找到相应参数组,请于后台属性模板中添加
search
Confirm
Close